Alto Neuroscience COO granted 131,000 stock options

Alto Neuroscience reported that its Chief Operating Officer, Michael Conick Hanley Jr., received an employee stock option grant.

Rhea-AI Filing Summary

Alto Neuroscience reported that its Chief Operating Officer, Michael Conick Hanley Jr., received an employee stock option grant. On February 11, 2026, he was awarded options to acquire 131,000 shares of common stock at an exercise price of $16.71 per share.

The options vest over four years: 25% of the underlying shares vest on February 11, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on his continued service with the company.

Insider Trade Summary

Grant/Award: 131,000 shares

Grant/Award 1 txn

Insider Hanley Jr. Michael Conick

Role CHIEF OPERATING OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	131,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 131,000 contracts (Direct)

Footnotes (1)

1. F1. 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Alto Neuroscience (ANRO) report for its COO?

Alto Neuroscience reported an option grant to COO Michael Conick Hanley Jr. He received stock options for 131,000 common shares at a $16.71 exercise price, forming part of his equity-based compensation, subject to a multi-year vesting schedule tied to continued service.

How many stock options did the Alto Neuroscience (ANRO) COO receive?

The COO received options covering 131,000 shares of Alto Neuroscience common stock. These options were granted on February 11, 2026, and represent a significant portion of his potential future equity, vesting over time as he remains employed by the company.

What is the exercise price of the Alto Neuroscience (ANRO) COO’s stock options?

The employee stock options were granted with an exercise price of $16.71 per share. This means the COO can buy Alto Neuroscience common stock at $16.71 once the options vest, aligning his potential upside with future share price performance over the vesting period.

What is the vesting schedule for the Alto Neuroscience (ANRO) COO’s option grant?

Twenty-five percent of the options vest on February 11, 2027. The remaining seventy-five percent vest in equal monthly installments over the following three years, provided the COO maintains continuous service with Alto Neuroscience through each monthly vesting date.

Is the Alto Neuroscience (ANRO) COO’s option grant an open market stock purchase?

No, this is an equity award, not an open market purchase. The filing describes it as an employee stock option grant, with 131,000 options awarded at a $16.71 exercise price, classified as an acquisition under a grant or award, rather than a market buy transaction.

How many derivative securities does the Alto Neuroscience (ANRO) COO hold after this grant?

After the grant, the COO beneficially owns 131,000 derivative securities in the form of employee stock options. These options are held directly and give him the right to acquire 131,000 shares of Alto Neuroscience common stock if exercised after vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 05:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hanley Jr. Michael Conick

(Last) (First) (Middle)

C/O ALTO NEUROSCIENCE, INC.

650 CASTRO STREET, SUITE 450

(Street)

MOUTAIN VIEW CA 94041

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alto Neuroscience, Inc. [ ANRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$16.71	02/11/2026		A		131,000		(1)	02/10/2036	Common Stock	131,000	$0	131,000	D

Explanation of Responses:

1. 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

	/s/ Erin R. McQuade, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.